Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Blood Pressure-Lowering Effect of Nebivolol in Hypertensive Patients with Type 2 Diabetes Mellitus: The YESTONO Study

Open access
Schmidt, Andre C, Graf, Christine, Brixius, Klara, Scholze, Juergen · 2007 · Clinical Drug Investigation

Abstract

Background Effective blood pressure (BP)-lowering therapy is regarded as the most important intervention in diabetes mellitus. Nebivolol is commonly used for the treatment of hypertension, but to date there has been no study of its use in a large population of hypertensive patients with type 2 diabetes mellitus.Methods A prospective, open-label, multicentre, post-marketing surveillance study was conducted in 2838 patients with arterial hypertension requiring intervention and concomitant type 2 diabetes, with or without other diseases. The therapeutic agent was nebivolol, either as monotherapy or as add-on therapy to other antihypertensive agents, over a minimum period of 3 months, with the primary endpoint being achievement of target BPs, that is, systolic BP < or = 140 mm Hg and diastolic BP < or = 90 mm Hg. Other endpoints were changes in metabolic parameters, effects on physical capability and tolerability during treatment. Statistical analysis was prospectively planned and conducted on an intention-to-treat basis.Results Mean (SD) BP decreased from 156 (15.3)/92 (9.4)mm Hg to 135 (11)/81 (6.6)mm Hg during the treatment period, while mean (SD) heart rate decreased from 79 (10) to 71 (7) beats/min. Strict reduction of BP was associated with improvements in most metabolic parameters, including lipid levels, glycosylated haemoglobin (HbA(1c)) and microalbuminuria. Maximum physical capability improved modestly. Most patients (85%) received nebivolol 5 mg/day.Conclusions Strict BP reduction in hypertensive patients with type 2 diabetes with or without other concomitant cardiovascular diseases is achieved with nebivolol 5 mg/day in most patients. The benefits of lowering BP with use of nebivolol are associated with improvements in most metabolic parameters and in maximum physical capability.

Overview

Integrity signals

Registry

Crossref · 10.2165/00044011-200727120-00006

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Research works printed but not linked: 3

  1. Buse, 2007, Circulation, 115, 114, 10.1161/CIRCULATIONAHA.106.179294 · DOI · Paper page
  2. Mancia, 2007, Eur Heart J, 28, 1462
  3. Korotkoff, 1905, Bull Imperial Mil Med Acad, 11, 365

Cited by

See all 46

Metadata

Authors
Schmidt, A. C., Graf, C., Brixius, K., & Scholze, J.
Affiliations
  • Charité – Universitätsmedizin Berlin (DE)
  • German Sport University Cologne (DE)
Corresponding author
Scholze, Juergen
Venue
Clinical Drug Investigation
Published
2007
Volume
27
Issue
12
Pages
841-849
ISSN
  • 0114-2402 (ISSN-L)
  • 1173-2563
OpenAlex
W1984366579
Cited by
46
References
44
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 2
FWCI
3.03
Type
journal article
Language
en
Open access
Licence
cc-by-sa
Locations
  • Clinical Drug Investigation (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
nebivolol, type 2 diabetes, hypertension, blood pressure reduction, beta-blockers, add-on antihypertensive therapy, glycosylated haemoglobin, microalbuminuria, serum lipids, physical abilities, heart rate reduction, post-marketing surveillance
MeSH terms
Nebivolol, Adrenergic beta-Antagonists, Adult, Aged, Aged, 80 and over, Albuminuria, Antihypertensive Agents, Benzopyrans, Blood Pressure, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Ethanolamines, Female, Heart Rate, Glycated Hemoglobin, Humans, Hypertension, Lipids, Male, Middle Aged, Product Surveillance, Postmarketing, Prospective Studies, Treatment Outcome, Exercise Tolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood Pressure-Lowering Effect of Nebivolol in Hypertensive Patients with Type 2 Diabetes Mellitus: The YESTONO Study. https://app.cochat.ai/papers/10.2165/00044011-200727120-00006
The paper
Schmidt, A. C., Graf, C., Brixius, K., & Scholze, J. (2007). Blood Pressure-Lowering Effect of Nebivolol in Hypertensive Patients with Type 2 Diabetes Mellitus: The YESTONO Study. Clinical Drug Investigation. https://doi.org/10.2165/00044011-200727120-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.